RxDoctor Payments Data

Ram Amilineni, MD

Internal Medicine · Orange City, FLNPI 1457457541

Payments from drug & device makers

$1,651in general payments, 2019–2025

Across 83 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$367
  • GSK$279
  • Novo Nordisk$218
  • Abbott$158
  • Medtronic$121
  • Johnson & Johnson$119
  • plus $390 from 10 others

What the payments were for

  • Food & beverage$1,651100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,651 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$291,074
Medicare patients
580
Services billed
3,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban287$172,779
JanuviaSitagliptin Phosphate204$103,866
NuplazidPimavanserin Tartrate19$64,270
OzempicSemaglutide51$63,107
ProcritEpoetin Alfa47$47,482
MounjaroTirzepatide33$45,953
JardianceEmpagliflozin72$45,500
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$39,548
XareltoRivaroxaban39$35,500
RybelsusSemaglutide33$33,912
TrulicityDulaglutide28$32,298
FarxigaDapagliflozin Propanediol33$30,549
EntrestoSacubitril/Valsartan23$25,082
CaplytaLumateperone Tosylate19$20,272
MyrbetriqMirabegron19$14,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$172,779287 claims
Novo NordiskOzempic, Rybelsus$218$97,01984 claims
Johnson & JohnsonProcrit, Xarelto$119$82,98386 claims
Lilly USA, LLCMounjaro, Trulicity$33$78,25161 claims
GSKTrelegy Ellipta$279$39,54840 claims
AstraZenecaFarxiga$108$30,54933 claims
AbbVieSynthroid$367$6,39371 claims
AmgenEpogen$36$3,02817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Orange City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →